Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor
Aims: Imatinib plasma trough levels (IM C min ) have been reported to have a considerable clinical impact in patients with gastrointestinal stromal tumors (GISTs). We therefore have investigated the factors affecting IM plasma concentration in Chinese GIST patients. Methods: IM C min in 190 patients...
Gespeichert in:
| Veröffentlicht in: | Chemotherapy (Basel) 2018-01, Vol.63 (6), p.301-307 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 307 |
|---|---|
| container_issue | 6 |
| container_start_page | 301 |
| container_title | Chemotherapy (Basel) |
| container_volume | 63 |
| creator | Wu, Xingye Li, Juan Zhou, Yi Mao, Yun Luo, Shiqiao He, Xuemei Wang, Li Shen, Yifan Zhang, Hua Yang, Longwei Zhang, Jun |
| description | Aims: Imatinib plasma trough levels (IM C min ) have been reported to have a considerable clinical impact in patients with gastrointestinal stromal tumors (GISTs). We therefore have investigated the factors affecting IM plasma concentration in Chinese GIST patients. Methods: IM C min in 190 patients with GIST who were taking IM were measured. Results: In patients treated with IM 300 mg/day (n = 16), 400 mg/day (n = 168), and > 400 mg/day (500: n = 1, 600: n = 5), IM C min was 1,564.54 ± 596.15, 1,521.26 ± 610.33, and 2,540.31 ± 1,298.14 ng/mL, respectively. Of the 168 patients treated with IM 400 mg/day, IM C min was significantly lower in males (1,353.94 ± 492.89 ng/mL) than in females (1,680.79 ± 669.03 ng/mL, p < 0.01), and in patients with gastrectomy (1,439.60 ± 587.66 ng/mL) than those without gastrectomy (1,649.88 ± 620.12 ng/mL) (p = 0.033). High IM C min was correlated with low body weight (p = 0.004) and low body surface area (p < 0.001). Conclusion: IM C min at steady state was significantly associated with body weight and body surface area. Monitoring of IM C min might be particularly important for the optimal treatment with IM of male patients and those who have undergone gastrectomy. |
| doi_str_mv | 10.1159/000493195 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000493195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2188591144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-bdf0bd8bbbdcbf81dd6709d40a81c2d842144eaf14f32271b2ab0108eb570d703</originalsourceid><addsrcrecordid>eNptkL1PwzAQxS0EoqUwsCNkiQWGgB0nTTJWUT-QKoGgzJEdO60hsYudgPrfcyilE9P53v38zn4IXVJyT2mcPRBCoozRLD5CQxqFNMiSLDpGQ9CzgNE4GaAz79-hZWNGT9GAkRRO43iI3Iuqeau_FJ7xsrXO44nh9c5rj22FHxuYGS3wytluvcG5NaUyrQPVGqwNzjfaKK_wMygw8Phbtxs85751VptWebjOa_wKbQN11TXWnaOTitdeXezrCL3Npqt8ESyf5o_5ZBmUjEVtIGRFhEyFELIUVUqlHCckkxHhKS1DmcI_o0jxikYVC8OEipALQkmqRJwQmRA2Qre979bZzw6eUjTal6quuVG280VI0zTOKLgAetejpbPeO1UVW6cb7nYFJcVvxMUhYmCv97adaJQ8kH-ZAnDTAx_crZU7APli2lsUW1kBdfUvtd_yA79yjRM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2188591144</pqid></control><display><type>article</type><title>Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor</title><source>MEDLINE</source><source>Karger Journals</source><creator>Wu, Xingye ; Li, Juan ; Zhou, Yi ; Mao, Yun ; Luo, Shiqiao ; He, Xuemei ; Wang, Li ; Shen, Yifan ; Zhang, Hua ; Yang, Longwei ; Zhang, Jun</creator><creatorcontrib>Wu, Xingye ; Li, Juan ; Zhou, Yi ; Mao, Yun ; Luo, Shiqiao ; He, Xuemei ; Wang, Li ; Shen, Yifan ; Zhang, Hua ; Yang, Longwei ; Zhang, Jun</creatorcontrib><description>Aims: Imatinib plasma trough levels (IM C min ) have been reported to have a considerable clinical impact in patients with gastrointestinal stromal tumors (GISTs). We therefore have investigated the factors affecting IM plasma concentration in Chinese GIST patients. Methods: IM C min in 190 patients with GIST who were taking IM were measured. Results: In patients treated with IM 300 mg/day (n = 16), 400 mg/day (n = 168), and > 400 mg/day (500: n = 1, 600: n = 5), IM C min was 1,564.54 ± 596.15, 1,521.26 ± 610.33, and 2,540.31 ± 1,298.14 ng/mL, respectively. Of the 168 patients treated with IM 400 mg/day, IM C min was significantly lower in males (1,353.94 ± 492.89 ng/mL) than in females (1,680.79 ± 669.03 ng/mL, p < 0.01), and in patients with gastrectomy (1,439.60 ± 587.66 ng/mL) than those without gastrectomy (1,649.88 ± 620.12 ng/mL) (p = 0.033). High IM C min was correlated with low body weight (p = 0.004) and low body surface area (p < 0.001). Conclusion: IM C min at steady state was significantly associated with body weight and body surface area. Monitoring of IM C min might be particularly important for the optimal treatment with IM of male patients and those who have undergone gastrectomy.</description><identifier>ISSN: 0009-3157</identifier><identifier>EISSN: 1421-9794</identifier><identifier>DOI: 10.1159/000493195</identifier><identifier>PMID: 30836365</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anticancer Section / Original Paper ; Antigens, CD34 - genetics ; Antineoplastic Agents - blood ; Antineoplastic Agents - therapeutic use ; Asian Continental Ancestry Group ; Body Surface Area ; Body Weight ; China ; Dose-Response Relationship, Drug ; Female ; Gastrectomy ; Gastrointestinal Stromal Tumors - drug therapy ; Gastrointestinal Stromal Tumors - pathology ; Gastrointestinal Stromal Tumors - surgery ; Humans ; Imatinib Mesylate - blood ; Imatinib Mesylate - therapeutic use ; Male ; Middle Aged ; Sex Factors</subject><ispartof>Chemotherapy (Basel), 2018-01, Vol.63 (6), p.301-307</ispartof><rights>2019 S. Karger AG, Basel</rights><rights>2019 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-bdf0bd8bbbdcbf81dd6709d40a81c2d842144eaf14f32271b2ab0108eb570d703</citedby><cites>FETCH-LOGICAL-c334t-bdf0bd8bbbdcbf81dd6709d40a81c2d842144eaf14f32271b2ab0108eb570d703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,2423,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30836365$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Xingye</creatorcontrib><creatorcontrib>Li, Juan</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Mao, Yun</creatorcontrib><creatorcontrib>Luo, Shiqiao</creatorcontrib><creatorcontrib>He, Xuemei</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Shen, Yifan</creatorcontrib><creatorcontrib>Zhang, Hua</creatorcontrib><creatorcontrib>Yang, Longwei</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><title>Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor</title><title>Chemotherapy (Basel)</title><addtitle>Chemotherapy</addtitle><description>Aims: Imatinib plasma trough levels (IM C min ) have been reported to have a considerable clinical impact in patients with gastrointestinal stromal tumors (GISTs). We therefore have investigated the factors affecting IM plasma concentration in Chinese GIST patients. Methods: IM C min in 190 patients with GIST who were taking IM were measured. Results: In patients treated with IM 300 mg/day (n = 16), 400 mg/day (n = 168), and > 400 mg/day (500: n = 1, 600: n = 5), IM C min was 1,564.54 ± 596.15, 1,521.26 ± 610.33, and 2,540.31 ± 1,298.14 ng/mL, respectively. Of the 168 patients treated with IM 400 mg/day, IM C min was significantly lower in males (1,353.94 ± 492.89 ng/mL) than in females (1,680.79 ± 669.03 ng/mL, p < 0.01), and in patients with gastrectomy (1,439.60 ± 587.66 ng/mL) than those without gastrectomy (1,649.88 ± 620.12 ng/mL) (p = 0.033). High IM C min was correlated with low body weight (p = 0.004) and low body surface area (p < 0.001). Conclusion: IM C min at steady state was significantly associated with body weight and body surface area. Monitoring of IM C min might be particularly important for the optimal treatment with IM of male patients and those who have undergone gastrectomy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticancer Section / Original Paper</subject><subject>Antigens, CD34 - genetics</subject><subject>Antineoplastic Agents - blood</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Asian Continental Ancestry Group</subject><subject>Body Surface Area</subject><subject>Body Weight</subject><subject>China</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Gastrectomy</subject><subject>Gastrointestinal Stromal Tumors - drug therapy</subject><subject>Gastrointestinal Stromal Tumors - pathology</subject><subject>Gastrointestinal Stromal Tumors - surgery</subject><subject>Humans</subject><subject>Imatinib Mesylate - blood</subject><subject>Imatinib Mesylate - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Sex Factors</subject><issn>0009-3157</issn><issn>1421-9794</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkL1PwzAQxS0EoqUwsCNkiQWGgB0nTTJWUT-QKoGgzJEdO60hsYudgPrfcyilE9P53v38zn4IXVJyT2mcPRBCoozRLD5CQxqFNMiSLDpGQ9CzgNE4GaAz79-hZWNGT9GAkRRO43iI3Iuqeau_FJ7xsrXO44nh9c5rj22FHxuYGS3wytluvcG5NaUyrQPVGqwNzjfaKK_wMygw8Phbtxs85751VptWebjOa_wKbQN11TXWnaOTitdeXezrCL3Npqt8ESyf5o_5ZBmUjEVtIGRFhEyFELIUVUqlHCckkxHhKS1DmcI_o0jxikYVC8OEipALQkmqRJwQmRA2Qre979bZzw6eUjTal6quuVG280VI0zTOKLgAetejpbPeO1UVW6cb7nYFJcVvxMUhYmCv97adaJQ8kH-ZAnDTAx_crZU7APli2lsUW1kBdfUvtd_yA79yjRM</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Wu, Xingye</creator><creator>Li, Juan</creator><creator>Zhou, Yi</creator><creator>Mao, Yun</creator><creator>Luo, Shiqiao</creator><creator>He, Xuemei</creator><creator>Wang, Li</creator><creator>Shen, Yifan</creator><creator>Zhang, Hua</creator><creator>Yang, Longwei</creator><creator>Zhang, Jun</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180101</creationdate><title>Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor</title><author>Wu, Xingye ; Li, Juan ; Zhou, Yi ; Mao, Yun ; Luo, Shiqiao ; He, Xuemei ; Wang, Li ; Shen, Yifan ; Zhang, Hua ; Yang, Longwei ; Zhang, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-bdf0bd8bbbdcbf81dd6709d40a81c2d842144eaf14f32271b2ab0108eb570d703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticancer Section / Original Paper</topic><topic>Antigens, CD34 - genetics</topic><topic>Antineoplastic Agents - blood</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Asian Continental Ancestry Group</topic><topic>Body Surface Area</topic><topic>Body Weight</topic><topic>China</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Gastrectomy</topic><topic>Gastrointestinal Stromal Tumors - drug therapy</topic><topic>Gastrointestinal Stromal Tumors - pathology</topic><topic>Gastrointestinal Stromal Tumors - surgery</topic><topic>Humans</topic><topic>Imatinib Mesylate - blood</topic><topic>Imatinib Mesylate - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Sex Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Xingye</creatorcontrib><creatorcontrib>Li, Juan</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Mao, Yun</creatorcontrib><creatorcontrib>Luo, Shiqiao</creatorcontrib><creatorcontrib>He, Xuemei</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Shen, Yifan</creatorcontrib><creatorcontrib>Zhang, Hua</creatorcontrib><creatorcontrib>Yang, Longwei</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chemotherapy (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Xingye</au><au>Li, Juan</au><au>Zhou, Yi</au><au>Mao, Yun</au><au>Luo, Shiqiao</au><au>He, Xuemei</au><au>Wang, Li</au><au>Shen, Yifan</au><au>Zhang, Hua</au><au>Yang, Longwei</au><au>Zhang, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor</atitle><jtitle>Chemotherapy (Basel)</jtitle><addtitle>Chemotherapy</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>63</volume><issue>6</issue><spage>301</spage><epage>307</epage><pages>301-307</pages><issn>0009-3157</issn><eissn>1421-9794</eissn><abstract>Aims: Imatinib plasma trough levels (IM C min ) have been reported to have a considerable clinical impact in patients with gastrointestinal stromal tumors (GISTs). We therefore have investigated the factors affecting IM plasma concentration in Chinese GIST patients. Methods: IM C min in 190 patients with GIST who were taking IM were measured. Results: In patients treated with IM 300 mg/day (n = 16), 400 mg/day (n = 168), and > 400 mg/day (500: n = 1, 600: n = 5), IM C min was 1,564.54 ± 596.15, 1,521.26 ± 610.33, and 2,540.31 ± 1,298.14 ng/mL, respectively. Of the 168 patients treated with IM 400 mg/day, IM C min was significantly lower in males (1,353.94 ± 492.89 ng/mL) than in females (1,680.79 ± 669.03 ng/mL, p < 0.01), and in patients with gastrectomy (1,439.60 ± 587.66 ng/mL) than those without gastrectomy (1,649.88 ± 620.12 ng/mL) (p = 0.033). High IM C min was correlated with low body weight (p = 0.004) and low body surface area (p < 0.001). Conclusion: IM C min at steady state was significantly associated with body weight and body surface area. Monitoring of IM C min might be particularly important for the optimal treatment with IM of male patients and those who have undergone gastrectomy.</abstract><cop>Basel, Switzerland</cop><pmid>30836365</pmid><doi>10.1159/000493195</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-3157 |
| ispartof | Chemotherapy (Basel), 2018-01, Vol.63 (6), p.301-307 |
| issn | 0009-3157 1421-9794 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000493195 |
| source | MEDLINE; Karger Journals |
| subjects | Adult Aged Aged, 80 and over Anticancer Section / Original Paper Antigens, CD34 - genetics Antineoplastic Agents - blood Antineoplastic Agents - therapeutic use Asian Continental Ancestry Group Body Surface Area Body Weight China Dose-Response Relationship, Drug Female Gastrectomy Gastrointestinal Stromal Tumors - drug therapy Gastrointestinal Stromal Tumors - pathology Gastrointestinal Stromal Tumors - surgery Humans Imatinib Mesylate - blood Imatinib Mesylate - therapeutic use Male Middle Aged Sex Factors |
| title | Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T06%3A45%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relative%20Factors%20Analysis%20of%20Imatinib%20Trough%20Concentration%20in%20Chinese%20Patients%20with%20Gastrointestinal%20Stromal%20Tumor&rft.jtitle=Chemotherapy%20(Basel)&rft.au=Wu,%20Xingye&rft.date=2018-01-01&rft.volume=63&rft.issue=6&rft.spage=301&rft.epage=307&rft.pages=301-307&rft.issn=0009-3157&rft.eissn=1421-9794&rft_id=info:doi/10.1159/000493195&rft_dat=%3Cproquest_cross%3E2188591144%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2188591144&rft_id=info:pmid/30836365&rfr_iscdi=true |